Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform

2 years ago

MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and industrialized by Atavistik Bio as…

Back-to-back Studies Validate geneType Breast Cancer Risk Test

2 years ago

MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…

ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders

2 years ago

A highly selective HDAC-6 inhibitorRescues motor-neuronal deficiencies in a Charcot-Marie-Tooth modelTo start IND enabling studiesMADRID, Spain and BOSTON, March 13,…

STRATA Skin Sciences Affirms No Exposure to Silicon Valley Bank

2 years ago

HORSHAM, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to…

PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference

2 years ago

BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of…

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

2 years ago

Patients treated with BIV201 experienced reduced ascites fluid buildup (pCARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc.,…

electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting

2 years ago

Poster Highlights the Ability of Non-Invasive Vagus Nerve Stimulation (nVNS) to Accelerate Learning of a Second LanguageROCKAWAY, N.J., March 13,…

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

2 years ago

OV329 Phase 1 trial is progressing on trackAn IV formulation candidate suitable for future clinical trials has been achieved for…

First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

2 years ago

BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ:…

Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

2 years ago

Chen Franco-Yehuda Chief Financial Officer Efrat Livne-Hadass Vice President of Human ResourcesHAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri…